4 Months on Mounjaro With No Weight Loss: What It Means (October 2026)

01 · The core answer

What no weight loss after 4 months usually means

No visible loss at this point usually points to one of a few ordinary explanations rather than to the medicine being useless for you. Mounjaro (tirzepatide) is licensed for weight management in adults, and it works alongside a reduced-calorie diet and increased physical activity, not instead of them.¹ If either side of that partnership has slipped, the scales can stand still even though your appetite feels different.

The first thing to ask is where you actually are on the dose ladder. Mounjaro comes in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹ The first weeks on 2.5mg are an adjustment phase and losses are usually modest. Most measurable progress builds from 5mg onward, month by month.¹ If you have stayed on a low strength for the whole period, or lost time to a pause, you may simply not have reached the dose that works for you yet.

The second question is how the weeks have gone in practice. Weight loss on Mounjaro is not linear. Plateaus of a few weeks are normal and expected as the body adapts to a lower weight. A flat patch after an early drop is a different situation from never having moved at all, and your prescriber will want to know which one you are in.

The third is what the trials actually show about pace. Average weight loss in SURMOUNT-1 built month by month, with the full averages measured at 72 weeks, not at this early point.² Slower early progress does not predict failure; the dose you respond to may still be ahead of you.² That is reassuring, but it is not a reason to wait passively. It is a reason to check the basics and talk to your prescriber.

02 · Your next step

The two decisions you are actually facing

The first decision is whether this is a pace problem or a response problem. A pace problem means you are still climbing the ladder, your appetite has changed, and the trend over several weeks is flat or slowly downward. A response problem means you have been on a meaningful dose for a sustained period with honest effort on food and activity, and the trend still does not move. Your prescriber is the right person to tell the two apart, using your dose history and your measurements rather than a single number.

The second decision is what to ask for. Within the licence, the responses to a stall are to review food intake honestly (portions drift back up), protect protein and activity, check the basics such as sleep and alcohol, and discuss with your prescriber whether a dose step-up is appropriate if you are not yet at maximum. A plateau is not a reason to double doses or add unlicensed products. Do not extend, stretch or combine pens to try to force a result.

Treatment response is reviewed by your prescriber: if you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.¹ That is a conversation, not a cliff edge, and it is based on your own record. Bring dose dates, weekly weights, a rough food diary and any side effects that have limited your dose.

If you are already a customer, our prescribing team carries out ongoing monthly reviews, dose-titration and follow-up assessments, so you can raise this with them directly. If you are still deciding whether treatment is right for you, the Mounjaro pen prices and consultation page shows the six strengths, with your first 2.5mg pen at £129.99 using code FIRST40 (standard price £169.99). For the wider picture, see our weight loss clinic overview.

You can also compare how this stage sits against earlier ones in our guides to three months without weight loss and two months without weight loss. The pattern across them is consistent: early flatness is common and usually explainable.

03 · The dose ladder and timing

Why your position on the dose ladder matters

Where you sit on the dose ladder is the single most useful fact for interpreting a quiet scale. Mounjaro is a once-weekly injectable made by Eli Lilly, supplied as a pre-filled multi-dose KwikPen in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹ The ladder exists because the body is introduced to the medicine gradually. The lowest strength is a starter dose, not a target dose.

The first weeks on 2.5mg are an adjustment phase and losses are usually modest. Most measurable progress builds from 5mg onward, month by month.¹ So if you lost nothing on the starter pen, that fits what you would expect. Where you are at this stage depends on whether you moved up on schedule, paused for side effects, or stayed on one strength longer than planned.

It is also worth knowing why a prescriber might hold you at a dose. Mild nausea, altered appetite and tiredness in the first days after each injection are the commonest early effects and usually settle.¹ If they have not settled, your prescriber may keep you where you are rather than step up. That is a sensible clinical choice, and it can explain a slower trend. It is not a failure on your part.

That is useful context if you are comparing how you feel on a low strength with what you read about higher ones. Low-strength experiences and high-strength experiences are genuinely different, so another person's account at a different strength is a weak guide to what you should see.

Practical step: write down the strength you took each week since you started, including any skipped or delayed weeks, and note the date of each change. A clear dose history lets your prescriber see in seconds whether this is a timing issue. If you have been stable on a strength for a good while and it is well tolerated, ask directly whether stepping up is appropriate. Never move up on your own, and never double doses to catch up.

The trial context supports patience with the ladder. In SURMOUNT-1, people on higher strengths lost more on average than those on lower strengths, measured over 72 weeks, alongside diet and exercise.² Those are trial averages, and individual results vary, but they show why the strength you are on is central to your expectations. You can read more about what the early weeks look like in our guide to Mounjaro results after four weeks.

04 · What trials show about pace

What the trials show about pace and averages

The headline trial figures describe a long course, so they should not be used to judge a single early checkpoint. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages, and individual results vary.

The important phrase is "over 72 weeks". The figures were measured at the end of a long treatment period, not partway through. Three months in, most people are still on the lower rungs of the dose ladder, so trial-average losses at that stage are modest compared with the headline figures. Average weight loss built month by month, with the full averages measured at 72 weeks, not at an early point.²

A sensible 3-month expectation on a standard titration is mid single digits as a percentage of body weight, with wide individual variation.² Wide variation means some people will be well ahead of that, and some will be behind it or flat. Being at the low end of a wide range is not the same as being outside it.

The trial also reports how many people reached certain milestones. At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight.² That shows that most trial participants achieved a meaningful loss over the full course, but it also shows the timescale: the figure belongs to the end of the study, not to the early months.

It helps to turn a percentage into something concrete without over-promising. For someone starting at 100 kg, 20.9% is about 21 kg, and that is the trial average on the highest strength at the end of the study period, not a target or a forecast for any individual at any particular month. Do not work backwards from a headline number to a weekly rate. Loss is uneven, and plateaus of a few weeks are normal.

Why does this matter for a stalled scale? Because many people compare themselves to a before-and-after story that reflects a longer period, a higher dose, or the most dramatic outcome, and conclude that they are failing. Comparing yourself with the trial average at the right timepoint, and on the right dose, is fairer. Our guide on how much you can expect to lose by this stage goes into the expectations in more depth.

Finally, remember the trial design: participants took the medicine alongside a reduced-calorie diet and increased physical activity, not instead of them. The comparison group with lifestyle changes alone lost far less on average, which shows both that the medicine adds something and that lifestyle remains part of the picture. If your routine has relaxed since the early weeks, that alone can flatten a trend.

05 · Plateaus and what to check

Plateaus: normal, and worth a methodical check

A plateau is a stretch where the trend stops moving, and on Mounjaro it is a normal feature rather than a malfunction. Weight loss on Mounjaro is not linear; plateaus of a few weeks are normal and expected as the body adapts to a lower weight.¹ A plateau of a few weeks deserves a calm review. A flat line that has run on since the start deserves a conversation with your prescriber.

Within the licence, the responses are practical and unglamorous. Review food intake honestly, because portions drift back up. Protect protein and activity. Check the basics, such as sleep and alcohol. And discuss with your prescriber whether a dose step-up is appropriate if you are not yet at maximum.¹ None of that is exotic, and that is the point: the common reasons for a stall are common.

Start with measurement. Weigh yourself under the same conditions, ideally at the same time of day, and look at the trend across several weeks rather than any single reading. Early loss includes water weight, so the trend over weeks matters more than any single weigh-in.¹ Day-to-day fluctuation can mask a slow downward trend, and it can also hide a slow upward one. Other measures, such as how clothes fit and how your waist feels, can show change when the scales do not.

Next, look at food. Reduced appetite does not automatically mean a reduced intake. Grazing, calorie-rich drinks and larger portions of soft, easy-to-eat foods can quietly restore the energy you were meant to cut. Tirzepatide helps most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹ It supports the diet; it does not replace it. A short, honest food diary for a couple of weeks often reveals what a memory of "eating very little" does not.

Then consider activity and recovery. Protecting activity does not mean punishing workouts. It means keeping regular movement in your week, and maintaining enough protein that you are not losing muscle along with fat. Poor sleep and regular alcohol both tend to work against appetite control and consistency, so they are on the checklist for a reason.

Last, be clear about what not to do. A plateau is not a reason to double doses, to use a pen beyond its labelled use, or to add unlicensed products. If you are tempted, tell your prescriber what you are considering instead.

06 · Food, protein and activity

Food, protein and activity: the part you control

Mounjaro is licensed for use alongside a reduced-calorie diet and increased physical activity, so the daily routine is part of the treatment rather than an optional extra.¹ If the scale has not moved, the most productive thing you can do this week is to look at your routine with the same seriousness as your dose.

Start by understanding what the medicine does. Tirzepatide activates two natural gut-hormone receptors at once, GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties and improve the way the body responds to insulin.¹ In practice, most people feel fuller sooner and less hungry between meals. That is a tool that makes eating less easier. It does not remove the energy in what you do eat.

Portions are the first place to look. Because fullness arrives sooner, many people start with small meals, then gradually serve larger portions as the early nausea eases and appetite returns. This is exactly the "portions drift back up" pattern. Using a smaller plate, serving once and not returning for seconds, and pausing mid-meal to check fullness can all help.

Liquid calories are the second place. Sweetened coffees, juices, alcohol and milkshakes are easy to consume when solid food feels unappealing. Because slowed stomach emptying can make large solid meals uncomfortable, some people drift towards drinks and soft snacks that are energy-dense but not filling. Noticing that pattern is half the fix.

Protein is the third. Protecting protein intake supports fullness and helps preserve muscle during weight loss. If your appetite is small, protein-first meals are an easy habit: eat the protein portion first, then add vegetables and carbohydrates as appetite allows. Your prescriber or a dietitian can personalise targets.

Activity is the fourth. You do not need to start extreme training. Regular walking, strength work you can sustain and reducing long unbroken sitting are all within reach. The aim is consistency across weeks, which is how trends are built. The trial participants lost weight alongside lifestyle changes, and the lifestyle-only comparison group lost far less, which shows the medicine and the lifestyle each matter.²

A practical way to test whether routine is the issue is a short, structured reset. For a couple of weeks, log what you eat, note drinks, keep your walking regular and fix a consistent sleep window. Compare the trend before and after. If nothing moves even with a tight routine on a well-tolerated dose, you have useful evidence to bring to your prescriber. If something moves, you have found your lever.

Be kind to yourself in the process. Rigid perfection is not required, and punishing restriction tends to backfire. The goal is a routine you could sustain for months, because the treatment itself is measured in months. If low mood, stress eating or a difficult relationship with food is part of the picture, say so; your prescriber would rather know than guess.

07 · The prescriber review

When your prescriber reviews response

Your response to treatment is formally reviewed, and the review has a defined trigger. Treatment response is reviewed by your prescriber: if you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.¹ Note the wording: it is the highest tolerated dose, not simply the time elapsed since your first injection.

That wording protects people who have been held at a lower strength for good reason. If side effects kept you on a modest dose, the clock that matters is time at the highest dose you could tolerate, not calendar time. It also means that someone who is still climbing the ladder is not being written off. The review is designed to ask whether the medicine is doing enough at the dose you can actually take.

What happens in a review conversation? Expect questions about your dose history, any gaps, side effects, appetite, eating pattern, activity and how your measurements have changed. Your prescriber may suggest continuing as you are, adjusting the dose, or revisiting whether treatment is the right fit. Stopping is one option among several, and it should be a joint decision, not an automatic one.

It helps to prepare. Bring a dated list of every dose, your weekly weights (or your best record of them), any waist or clothing changes, and a candid description of food and drinks. If you have been tempted to try something outside the plan, mention it. A prescriber can only help you within a clinical framework if they know what is actually happening.

At EverydayMeds, prescribing is carried out by GPhC-registered prescribers, and our aftercare includes ongoing monthly reviews, dose-titration and follow-up assessments, plus side-effect support. Repeat orders re-check suitability, and there is no auto-shipping, so each order is a deliberate decision rather than a default. Support is available Monday to Friday, 9am to 5pm, by email at support@everydaymeds.co.uk, through the account portal chat or by phone on 0333 207 0413.

If the outcome of a review is to adjust, that means a conversation about whether a step-up is appropriate if you are not yet at maximum, or whether another approach suits you better. Do not treat a review as an accusation. It is the mechanism that keeps treatment honest, so that you continue because it is working or change course because it is not.

If you have not reached that point yet, the review is still a useful target. Aim to arrive at it with a good record and a clear question, rather than waiting for it to arrive and then trying to remember what happened.

08 · Beyond the scales

Other changes the scales do not show

A flat scale does not necessarily mean nothing is changing. In trials, weight loss on tirzepatide came with average improvements in waist size, blood pressure, cholesterol and blood-sugar measures, and most participants with prediabetes returned to normal blood-sugar levels.² These are trial-average secondary outcomes, not promises, but they explain why prescribers talk about weight management as health management rather than appearance.

So what can you measure besides weight? A tape measure at the waist is a straightforward place to start, taken at the same point on the body each time. How your clothes fit, how you feel climbing stairs, and how often you think about food are all informative, even if they feel subjective. If you have a blood pressure monitor at home, or regular checks through your GP, those readings may tell their own story.

Remember that early loss includes water weight, so the trend over weeks matters more than any single weigh-in.¹ The reverse is also true: shifts in water, muscle and fat can partly offset each other in the short term, so the scale can understate what is happening. Combining several measures gives a fairer picture than relying on one.

This is not a way of excusing a lack of progress. If your measurements and your weight are both flat after sustained effort on a well-tolerated dose, that is information your prescriber needs. But for many people, discovering that their waist, energy or eating pattern has changed is a reassurance that the treatment is doing something, and helps them stay the course while the dose catches up.

It is also worth separating weight from wellbeing. Reduced "food noise", easier portion control and a better relationship with hunger are the experiences many people value, and they are not always reflected in the number. Mild nausea, altered appetite and tiredness in the first days after each injection are the commonest early effects and usually settle.¹ If they have settled and you feel more in control around food, that is progress worth noting even if the scale is slow.

If you want a visual reference of progress over a similar timescale, our guide on Mounjaro before and after at two months explains how to interpret early comparisons and why photographs and weights from different people are not directly comparable.

09 · Reading before and after stories

How to read before-and-after stories

Before-and-after images and stories are the least reliable benchmark for your own progress, because they show the most striking outcomes, not the typical ones. A person whose photographs look dramatic may be on a higher dose, may have been on treatment for much longer, or may be an outlier. Treat such stories as illustrations, not forecasts.

What should you compare against instead? The fair comparison is the trial average at a similar timepoint and dose, with wide individual variation in mind. In SURMOUNT-1, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² At an early point, the expected figure is much smaller, because the dose ladder and the timeline have not played out.

Individual results vary. Some people lose more than the average, some less, and some very little in the early phase. Slower early progress does not predict failure, because the dose you respond to may still be ahead of you.² That is the single most useful sentence to hold on to when scrolling through other people's results.

Photographs also hide context. They rarely show dose, adherence, diet quality, activity, starting weight or how long the person has been on treatment. Lighting, posture and clothing change appearance dramatically. Two images taken on different days can suggest changes that are not real, or hide changes that are.

If you want to track your own story fairly, take measurements and photographs under consistent conditions, at a consistent interval, and record your dose each time. A free companion app, GLPTrackr, is available for iOS and Android to help you log your GLP-1 journey. A log is more useful at a prescriber review than memory, and it protects you from the distortion of comparing with the highlight reel.

Finally, be cautious about stories that promise specific results or dramatic transformations on a fast timescale. Treatment works gradually, and results depend on dose, routine and individual response. If something sounds too good to be true, it probably describes a best case, or something that is not a licensed regimen. Our existing guide on how early before-and-after changes happen sets out what the mechanism can and cannot explain.

10 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

11 · Cost, NHS and ordering

Cost, NHS access and staying on treatment

If you are weighing whether to continue, change course or begin treatment, cost and access are fair practical questions. Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

For private treatment, the standard price of each pen depends on the dose. A new customer gets £40 off their first order at any dose with code FIRST40, and every future order gets an automatic £25 off (code DOSE25). If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices. A first year costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg, again at standard prices before discounts. Prices were checked 11 October 2026. You can see current prices for every strength on the Mounjaro pen page.

If you are already on treatment elsewhere and considering a switch at a higher strength, the first-order discount applies at any dose, and your first order at 15mg is £289.99. Your prescriber still decides what dose is appropriate for you.

How does ordering work with us? There is a free online consultation, a short health questionnaire with no charge and no obligation. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Orders are dispensed by our registered pharmacy (GPhC 9012878), with same-day dispatch when ordered by 3pm, and free next-day tracked delivery in temperature-controlled, discreet packaging. Saturday delivery is £14.99. All six doses are in stock, supplied through official LillyDirect supply from Eli Lilly's UK distribution.

Payment can be by Visa or Mastercard, Klarna or pay-monthly options, and there are no subscriptions. Needles, a sharps bin and injection guidance are included with every order. You can also store pens correctly: keep unopened pens in the fridge at 2–8°C and never freeze them; once in use, a pen can be kept out of the fridge at a temperature not above 30°C for up to 30 days after first use, and must then be thrown away.

Whatever you decide, treat it as a clinical decision, not a reaction to a single flat month. Mounjaro is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber, and it is used alongside a reduced-calorie diet and increased physical activity. Individual results vary. This page is information, not a substitute for medical advice.